|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0400 - 0.0465|
|52 Week Range||0.0200 - 0.1300|
|Beta (5Y Monthly)||0.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LAS VEGAS, NV / ACCESSWIRE / April 27, 2021 / GB Sciences (GBS), Inc. (OTCQB:GBLX), a leading phytomedicine research and biopharmaceutical development company, will be featured during the SPOTLIGHT SHOWCASE at the SACHS Associates' 4th Annual Neuroscience Innovation Forum (NIF) for Business Development, Licensing & Investment from April 28 to April 30.
Purisys will supply ultra-high purity cannabinoids for use in GB Sciences' cannabinoid-containing, optimized therapeutic mixtures (OTM).LAS VEGAS, NV / ACCESSWIRE / April 20, 2021 / GB Sciences, Inc.
GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market.